Press releaseGlobe Newswire
SpringWorks Therapeutics
SWTX · NASDAQ
Price unavailable right now.
No price history for this range.
Latest news
- Press releaseGlobe Newswire
European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors
- Press releaseGlobe Newswire
SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors
- Press releasePRNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPOF, PRA, SWTX on Behalf of Shareholders
- Press releaseBusiness Wire
SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX
- Press releasePRNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PRA, AXL, SWTX, VIGL on Behalf of Shareholders
- Press releasePRNewswire
$HAREHOLDER NOTICE: The M&A Class Action Firm Continues To Investigate The Merger - PRA, AXL, SWTX and VIGL
- Press releaseGlobe Newswire
SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN
- Press releasePRNewswire
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Its Investigation Into The Merger - PRA, KRON, AXL, SWTX
- Press releasePRNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, SWTX on Behalf of Shareholders
- Press releaseBusiness Wire
SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX
- Press releasePRNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWTX, RDUS, ALBT, BRDG on Behalf of Shareholders
- Press releasePRNewswire
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of SpringWorks Therapeutics, Inc. - SWTX
- Press releasePRNewswire
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of SpringWorks Therapeutics, Inc.
- News
Analyst Expectations For SpringWorks Therapeutics's Future
- NewsLekha Gupta
Merck Germany Buys US Cancer Drugmaker SpringWorks Therapeutics For Around $4 Billion
- Press releaseBusiness Wire
Shareholder Alert: The Ademi Firm Investigates Whether SpringWorks Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders
- Press releaseBusiness Wire
SWTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of SpringWorks Therapeutics, Inc. Is Fair to Shareholders
- Press releaseGlobe Newswire
Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business
- Press releaseBusiness Wire
Merck KGaA, Darmstadt, Germany, to Acquire US Biopharma Company SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business
- Press releaseGlobe Newswire
SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union
- News
10 Health Care Stocks Whale Activity In Today's Session
- News
Assessing SpringWorks Therapeutics: Insights From 6 Financial Analysts
- NewsAvi Kapoor
Top 3 Health Care Stocks You May Want To Dump In February
- Press releaseGlobe Newswire
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates
- News
Earnings Scheduled For February 20, 2025
- Press releasePRNewswire
SpringWorks Therapeutics and Jewelry Designer Jennifer Fisher Team Up to Encourage People with Desmoid Tumors to Take Action Before Their Tumor Takes Over
- Press releaseGlobe Newswire
UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
- Press releaseGlobe Newswire
SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
- NewsVandana Singh
Germany's Merck In Talks To Buy Cancer Drug Maker SpringWorks Therapeutics
- NewsAvi Kapoor
Crude Oil Rises Sharply; Manhattan Associates Shares Slide
- News
Smart Money Is Betting Big In SWTX Options
- NewsAvi Kapoor
Nasdaq Surges 1%; ON Semiconductor Shares Plunge Following Earnings Miss
- News
10 Health Care Stocks With Whale Alerts In Today's Session
- NewsLekha Gupta
Plug Power, Capri And Frontline Are Among Top Mid Cap Gainers Last Week (Jan 6-10): Are The Others In Your Portfolio?
- Press releasePRNewswire
Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon
- Press releaseGlobe Newswire
SpringWorks Therapeutics Announces Long-Term Efficacy and Safety Data from Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors to be Presented at the Connective Tissue Oncology Society (CTOS) 2024 Annual Meeting
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.